Abstract

The human hematopoietic stem cell harbors remarkable regenerative potential that can be harnessed therapeutically. During early development, hematopoietic stem cells in the fetal liver undergo active expansion while simultaneously retaining robust engraftment capacity, yet the underlying molecular program responsible for their efficient engraftment remains unclear. Here, we profile 26,407 fetal liver cells at both the transcriptional and protein level including ~7,000 highly enriched and functional fetal liver hematopoietic stem cells to establish a detailed molecular signature of engraftment potential. Integration of transcript and linked cell surface marker expression reveals a generalizable signature defining functional fetal liver hematopoietic stem cells and allows for the stratification of enrichment strategies with high translational potential. More precisely, our integrated analysis identifies CD201 (endothelial protein C receptor (EPCR), encoded by PROCR) as a marker that can specifically enrich for engraftment potential. This comprehensive, multi-modal profiling of engraftment capacity connects a critical biological function at a key developmental timepoint with its underlying molecular drivers. As such, it serves as a useful resource for the field and forms the basis for further biological exploration of strategies to retain the engraftment potential of hematopoietic stem cells ex vivo or induce this potential during in vitro hematopoietic stem cell generation.

During human embryonic development, haematopoietic stem cells of the foetal liver undergo expansion, while retaining engraftment capacity. Here the authors apply CITE-seq to profile single cells from a human foetal liver, identifying a molecular signature of engraftment potential

Details

Title
Multi-modal profiling of human fetal liver hematopoietic stem cells reveals the molecular signature of engraftment
Author
Kim, Vanuytsel 1   VIAFID ORCID Logo  ; Villacorta-Martin, Carlos 2 ; Lindstrom-Vautrin, Jonathan 2 ; Wang, Zhe 3   VIAFID ORCID Logo  ; Garcia-Beltran, Wilfredo F 4 ; Vrbanac Vladimir 4 ; Parsons, Dylan 4   VIAFID ORCID Logo  ; Lam, Evan C 4 ; Matte, Taylor M 2 ; Dowrey, Todd W 2   VIAFID ORCID Logo  ; Kumar, Sara S 2 ; Li, Mengze 3   VIAFID ORCID Logo  ; Wang, Feiya 2 ; Yeung, Anthony K 2   VIAFID ORCID Logo  ; Mostoslavsky Gustavo 2   VIAFID ORCID Logo  ; Dries Ruben 5 ; Campbell, Joshua D 3   VIAFID ORCID Logo  ; Belkina, Anna C 6   VIAFID ORCID Logo  ; Balazs, Alejandro B 4   VIAFID ORCID Logo  ; Murphy, George J 1 

 Boston University, Section of Hematology and Medical Oncology, School of Medicine, Boston, USA (GRID:grid.189504.1) (ISNI:0000 0004 1936 7558); Boston University and Boston Medical Center, Center for Regenerative Medicine (CReM), Boston, USA (GRID:grid.189504.1) (ISNI:0000 0004 1936 7558) 
 Boston University and Boston Medical Center, Center for Regenerative Medicine (CReM), Boston, USA (GRID:grid.189504.1) (ISNI:0000 0004 1936 7558) 
 Boston University, Division of Computational Biomedicine, School of Medicine, Boston, USA (GRID:grid.189504.1) (ISNI:0000 0004 1936 7558) 
 Ragon Institute of MGH, MIT and Harvard, Cambridge, USA (GRID:grid.461656.6) (ISNI:0000 0004 0489 3491) 
 Boston University, Section of Hematology and Medical Oncology, School of Medicine, Boston, USA (GRID:grid.189504.1) (ISNI:0000 0004 1936 7558); Boston University, Division of Computational Biomedicine, School of Medicine, Boston, USA (GRID:grid.189504.1) (ISNI:0000 0004 1936 7558) 
 Boston University, Department of Pathology and Laboratory Medicine, School of Medicine, Boston, USA (GRID:grid.189504.1) (ISNI:0000 0004 1936 7558); Boston University, Flow Cytometry Core Facility, School of Medicine, Boston, USA (GRID:grid.189504.1) (ISNI:0000 0004 1936 7558) 
Publication year
2022
Publication date
2022
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2634669384
Copyright
© The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.